Canadian Stock Trader

Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development

Written by

in

Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built 

Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built

Originally published via Source Article.

More posts